patient engagement: challenges of engaging …patient engagement: challenges of engaging patients...
TRANSCRIPT
![Page 1: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/1.jpg)
Patient Engagement: Challenges of Engaging Patients
and Patient GroupsRyan Hohman, Vice President--Public Affairs, Friends of Cancer Research
Tim Kreidler, Sr. Director of Regulatory Affairs – Commercialization, Dermira, Inc.
Jennifer Romanski, Principal, Porzio, Bromberg & Newman, P.C.
Moderated by Abraham Gitterman, Associate, Arnold & Porter LLP
![Page 2: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/2.jpg)
Speakers*
• Ryan Hohman, Vice President–Public Affairs, Friends of Cancer Research
• Tim Kreidler, Sr. Director of Regulatory Affairs – Commercialization, Dermira, Inc.
• Jennifer Romanski, Principal, Porzio, Bromberg & Newman, P.C.
• Moderated by Abraham Gitterman, Senior Associate, Arnold & Porter LLP
*The views and ideas expressed during this presentation are the speaker’s own and should not be attributed to their company, organization, firm or firm clients.
![Page 3: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/3.jpg)
Agenda
• Brief Overview of Current Landscape
• Q&A
![Page 4: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/4.jpg)
Why the Focus on Patients?
• FDA and Patient Focused Drug Development (PFDD) meetings
• 21st Century Cures Act and “patient experience data”
• Increased use of social/digital media for branded and unbranded initiatives
• Focus on rare and orphan diseases
• Growth, sophistication of patient organizations
• Significant focus on drug costs and price increases
• Independent co-pay foundation scrutiny, investigations, settlements
![Page 5: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/5.jpg)
Patient Groups: Overview
• Disease or condition-specific
• Established/historic vs. new
• Vary in size, scope, mission (e.g., international, national, regional, local)• Different budgets/operating money• Different initiatives or program offerings (e.g., R&D, grants, education)• Lobbying vs. no advocacy• May interact with government agencies (e.g., FDA, CMS, NIH)
• Conflict of interest policy
• No specific FDA or OIG rules/regulations addressing interactions with patient groups
![Page 6: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/6.jpg)
Congress and Patient Groups (Jun. 2019)
![Page 7: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/7.jpg)
Congress and Patient Groups (cont’d)
![Page 8: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/8.jpg)
Patient Groups & Media
8
![Page 9: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/9.jpg)
9
Patient Groups & Media (cont’d)
![Page 10: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/10.jpg)
Calls for Increased Transparency
![Page 11: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/11.jpg)
Integrating the Patient Voice
Define Patient Journey• Early Insight
• Ethnography
• Social Listening
• Patient Profile Library
• Patient Panels
• Inform IND & Protocol
Patient Input• Clinical Study Design
• PRO Development
• Trial Recruitment/Patient Ads
• Advocacy & Social Groups Communication & Materials
• Healthcare Literacy
Patient Insight• Marketing / Access
• Payer Advisory
• Program Design & Patient Services
• Publications
Drug Discovery
Non-Clinical
Clinical Phase I
Clinical Phase 2
Clinical Phase 3
FDA Filing LaunchPost
Approval
![Page 12: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/12.jpg)
Q&A
• What function within a pharmaceutical or medical device manufacturer should “own” interactions with patient groups?• Commercial (e.g., sales/marketing)?
• Medical?
• Corporate Affairs/Communications?
• Other (dedicated function i.e., Patient Affairs)
• Why? What are some of the potential issues/concerns?
![Page 13: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/13.jpg)
Q&A
• Is it appropriate for manufacturers and patient groups to collaborate on unbranded or disease awareness activities?
• If so, what things should both parties consider?• Transparency?
• Accuracy and consistency in content?
• Financial relationship?
• FDA regulations?
• What are some of the potential risks?
![Page 14: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/14.jpg)
Q&A
• Are there any recent FDA or other enforcement updates to consider for branded content including patients?• Patient ambassadors?
• Patient testimonials?
• Social media?
• What interactions, if any, should manufacturers have with patient groups regarding branded content?
![Page 15: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/15.jpg)
Q&A
• Are manufacturers or patient groups ready to for consistent with FDA-label (CFL) data?
• Can manufacturers use CFL data with a patient or patient group audience?
![Page 16: Patient Engagement: Challenges of Engaging …Patient Engagement: Challenges of Engaging Patients and Patient Groups Ryan Hohman, Vice President--Public Affairs, Friends of Cancer](https://reader033.vdocuments.mx/reader033/viewer/2022043019/5f3b873138c16d159d5db0fb/html5/thumbnails/16.jpg)
Q&A
• What are some of the risks or issues associate with patient support or access materials?• Adherence or reminder messaging?
• Convenience or quality of life messaging?
• Product administration and training?
• Fraud and abuse risks?
• Are these types of materials important to patient groups? • What information are they looking for?